|
What is CAR T cell therapy?
T cells are part of our immune system and help the body fight diseases such as cancer. CAR T cell therapy is a type of cancer treatment that uses the patient’s immune system to fight the disease. It’s a new and promising approach, especially for certain types of blood cancers, such as leukaemia and lymphoma.
How does CAR T cell therapy work?
• T cell collection: T cells are a type of white blood cell that are part of the immune system and typically help protect against infections. The most common process for making a CAR T cell therapy begins by collecting these T cells from the patient’s blood, usually using a method known as “leukapheresis”.
• T cell reprogramming: in a specialised laboratory, T cells are reprogrammed to recognise and attack cancer cells. Scientists manage this by adding a new gene to the T cells, enabling them to produce special proteins called “Chimeric Antigen Receptors” (CARs). These CARs act as homing devices, helping the T cells identify and destroy cancer cells. • T cell expansion: after reprogramming, the CAR T cells are grown and expanded in the laboratory to the necessary quantities for a clinical dose. • Reinfusion into the patient’s body: after the production process, the CAR T cells are collected and tested to assess safety and potency (efficacy). They are then reintroduced into the patient’s body through an intravenous infusion. Once inside the body, the CAR T cells seek and destroy cancer cells. Why are CAR T cell therapies promising?
CAR T cell therapy has been demonstrating promising results in patients with haematological malignancies who have failed initial treatment. In most cases, there is an immediate response to CAR T cell treatment, achieving prolonged remissions in many patients. However, relapses are still observed, highlighting the need for continued research in this area.
Can CAR T cell therapies have secondary effects?
Yes, there can be serious side effects. Doctors carefully monitor patients and are prepared to treat these effects if they arise. The most common side effects observed include:
• Cytokine Release Syndrome (CRS): This occurs when the immune system overreacts to treatment, causing symptoms such as high fever, low blood pressure, or difficulty breathing. • Neurologic alterations: Some people may experience confusion, headaches, or seizures. • Reduction in blood cells: After treatment, there may be a temporary decrease in circulating red and white blood cells. Who is eligible for CAR T cell therapy?
Currently, CAR T cell therapy is approved for certain types of blood cancers and is generally used when the patient fails to respond to previous lines of treatment. Scientists are also studying the application in solid tumours such as breast and lung cancer.
What is "T cell exhaustion", and why is this a challenge in CAR T cell therapy?
T cell exhaustion occurs when T cells are overworked for a long time, becoming “exhausted” and losing their ability to function effectively. This often happens when they are exposed to cancer cells for an extended period, becoming an even greater challenge for the treatment of solid tumours due to the immunosuppressive tumour microenvironment (TME). Exhaustion is also observed in engineered CAR T cells, meaning that the modified T cells may lose their function before they can fully remove the cancer. Understanding and preventing this exhaustion can help to make the treatment more lasting and effective, especially for solid tumours.
What is Gene Editing, and how is it being used in the context of CAR T cell therapy?
Gene editing is a method that allows scientists to modify specific regions of DNA within a cell. In CAR T cell therapy, gene editing tools can be used to insert, delete or regulate genes that enhance the safety and performance of the modified T cells. This can, for example, make the CAR T cells work more effectively, stay active for longer (greater resistance to exhaustion), or make the treatment safer for patients.
How is the Modifying Gene delivered into the T cells?
To go from a patient’s own T cell to an engineered CAR T cell, a new gene is added to the cell's genetic material, which helps to recognise and attack cancer cells. This is generally achieved using gene delivery tools, such as a modified virus (inactive), or novel non-viral technologies. The CAR T-REX project is exploring new ways to insert these genes more precisely and efficiently, to make the process safer and more cost effective, thereby increasing accessibility of these treatments to patients in need.
How are the improvements regarding Exhaustion, Gene Editing and delivery Technologies connected in the CAR T-REX project?
These three areas form the foundation of the CAR T-REX project’s innovation strategy: to make CAR T cell therapy more effective and reliable. By helping the CAR T cells stay active for longer (less exhaustion), improving how the cells are modified (gene editing), and making the process simpler and safer (novel delivery technologies), the project aims to create the next generation of CAR T cells with enhanced persistence, safety and therapeutic impact. Together, these advances support the overall goal of developing more effective and accessible cell-based cancer therapies in Europe.
|
|
Translated FAQ versions are available below.
